- Home
- FEED vs GRI Comparison
FEED vs GRI Comparison
Compare FEED & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEED | GRI |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FEED | GRI |
|---|---|---|
| Price | $3.02 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 36.0K | ★ 1.4M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.93 | $0.33 |
| 52 Week High | $162.50 | $15.64 |
Technical Indicators
Market Signals| Indicator | FEED | GRI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 20.17 |
| Support Level | N/A | $0.50 |
| Resistance Level | N/A | $2.17 |
| Average True Range (ATR) | 0.00 | 0.16 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 0.33 |
Price Performance
Historical ComparisonAbout GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.